Actavis Inc (ACT) 209.09 $ACT
Several IBD 50 Names Set Up In Stock Picker's Market
at Investor's Business Daily - Fri Jun 06, 4:58PM CDT
A nascent market uptrend, confirmed by the Nasdaq and S&P 500 on May 27, is looking pretty good. Distribution days, or higher-volume declines, have been nonexistent so far and growth stocks overall are holding up well. The IBD 50 is essentially flat...
The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market
More Stock Leaders Emerge From More Industry Groups
at Investor's Business Daily - Thu Jun 05, 5:03PM CDT
The set of 16 charts on IBD Stock Spotlight's computer-run screen are showing two promising new trends. The first trend: Since the Nasdaq's May 27 confirmation of a new market uptrend, more stocks are hitting proper buy points, while others are...
Chicago sues painkiller firms
at Investor's Business Daily - Tue Jun 03, 5:56PM CDT
Following the lead of Calif.'s Orange and Santa Clara counties, Chicago is suing 5 drugmakers, alleging their marketing downplayed the risk of FDA-approved opioids in treating chronic pain. The city wants to recover profits, along with civil...
Top New Buys: Funds Pile Into Actavis, chip stocks
at Investor's Business Daily - Tue Jun 03, 5:35PM CDT
After a three-month-long correction, the Nasdaq composite index followed through on March 27. That means it's time to look for stocks breaking out of sound bases. But mutual funds have already been busy in recent months, their buying helping to form...
Health Care Sector Equities Scrutiny -- Research on AVANIR Pharma, Zoetis, Actavis, and Mallinckrodt
PR Newswire - Tue Jun 03, 6:50AM CDT
On Monday, June 2, 2014, the NASDAQ Composite ended at 4,237.20, down 0.13%, the Dow Jones Industrial Average edged 0.16% higher to finish the day at 16,743.63, and the S&P 500 closed at 1,924.97, up 0.07%. During the session gains in the Materials, Industrials, and Consumer Discretionary sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Energy, and Information Technology sectors. The S&P 500 Health Care Sector Index ended the day at 691.40, up 0.17%, with the index advancing 3.37% in the last one month. Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT) and Mallinckrodt PLC (NYSE: MNK). Free technical research on AVNR, ZTS, ACT and MNK can be downloaded upon signing up at:
Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...
New Employers Listed For Annual Life Science Hiring Event
PR Newswire - Mon Jun 02, 9:45AM CDT
HireLifeScience.com, the premier career networking website for the Life Science industries, will host its 5th annual career fair at The NJ Convention and Exposition Center at Raritan Center in Edison, NJ on September 30, 2014. The annual hiring event is being sponsored by Novo Nordisk. Additional event sponsors thus far include Covance and top generic drug company, Actavis, Inc. In addition to returning companies such as Johnson & Johnson, LifeCell and Cubist Pharmaceuticals there have been many companies added since April. Recent additions to the exhibitor list are Daiichi Sankyo, Musculoskeletal Transplant Foundation (MTF), DSM Nutritional Products, Acorda Therapeutics, GE Healthcare, Amneal Pharmaceuticals and Actavis, Inc. More companies will be added during the upcoming summer months creating the largest Life Science career fair for 2014 in the Tri-State area.
Enzo Biochem names James M O'Brien as senior VP of Finance
M2 - Mon Jun 02, 6:03AM CDT
Clinical laboratory company Enzo Biochem (NYSE:ENZ) revealed on Friday the election of James M O'Brien as senior vice president of its Finance, succeeding Andrew Crescenzo.
Actavis Announces Nuvigil® Patent Challenge Settlement
PR Newswire - Fri May 30, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil® (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil® is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy.
1 Big Pharma Stock in More Danger than Investors Realize
David Williamson, The Motley Fool - Motley Fool - Fri May 30, 1:05PM CDT
Eli Lilly (NYSE: LLY) just lost a patent fight for its lung cancer drug Alimta to generic drug maker Actavis (NYSE: ACT). This UK court decision would cut the blockbuster drug's patent short by 6 years to 2015, not only in the United Kingdom,...
Enzo Biochem Announces Appointment of James M. O'Brien as Senior VP, Finance
Business Wire - Fri May 30, 8:01AM CDT
Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biosciences and clinical laboratory company, announced today the appointment of James M. O'Brien as Senior Vice President, Finance.
Many Weekly Review Stocks Still Nearing Buy Points
at Investor's Business Daily - Thu May 29, 5:50PM CDT
The market this week signaled a confirmed uptrend, which makes this a crucial time to find stocks to buy at proper buy points. Many leading stocks have already broken out past buy points. That's especially true in transportation, energy and food,...
Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.
Actavis Confirms Generic Onglyza® Patent Challenge
PR Newswire - Tue May 27, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza®, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Actavis Builds Base As Annual Earnings Keep Growing
at Investor's Business Daily - Fri May 23, 4:11PM CDT
It's been a busy year for Actavis (ACT) as it continues to grow through acquisitions. The former Watson Pharmaceuticals renamed itself Actavis after buying the latter drugmaker in 2012. In October it bought Irish pharmaceutical Warner Chilcott for...
Forest Laboratories, Inc. Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Thu May 22, 7:31AM CDT
Forest Laboratories, Inc. (NYSE: FRX) today announced that, subject to the close of the pending acquisition (the "Acquisition"
of Forest by Actavis plc (NYSE: ACT), Actavis is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.
Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations
PR Newswire - Thu May 22, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition" of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.
Several IBD 50 Names Set Up In Stock Picker's Market
at Investor's Business Daily - Fri Jun 06, 4:58PM CDT
A nascent market uptrend, confirmed by the Nasdaq and S&P 500 on May 27, is looking pretty good. Distribution days, or higher-volume declines, have been nonexistent so far and growth stocks overall are holding up well. The IBD 50 is essentially flat...
The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market
More Stock Leaders Emerge From More Industry Groups
at Investor's Business Daily - Thu Jun 05, 5:03PM CDT
The set of 16 charts on IBD Stock Spotlight's computer-run screen are showing two promising new trends. The first trend: Since the Nasdaq's May 27 confirmation of a new market uptrend, more stocks are hitting proper buy points, while others are...
Chicago sues painkiller firms
at Investor's Business Daily - Tue Jun 03, 5:56PM CDT
Following the lead of Calif.'s Orange and Santa Clara counties, Chicago is suing 5 drugmakers, alleging their marketing downplayed the risk of FDA-approved opioids in treating chronic pain. The city wants to recover profits, along with civil...
Top New Buys: Funds Pile Into Actavis, chip stocks
at Investor's Business Daily - Tue Jun 03, 5:35PM CDT
After a three-month-long correction, the Nasdaq composite index followed through on March 27. That means it's time to look for stocks breaking out of sound bases. But mutual funds have already been busy in recent months, their buying helping to form...
Health Care Sector Equities Scrutiny -- Research on AVANIR Pharma, Zoetis, Actavis, and Mallinckrodt
PR Newswire - Tue Jun 03, 6:50AM CDT
On Monday, June 2, 2014, the NASDAQ Composite ended at 4,237.20, down 0.13%, the Dow Jones Industrial Average edged 0.16% higher to finish the day at 16,743.63, and the S&P 500 closed at 1,924.97, up 0.07%. During the session gains in the Materials, Industrials, and Consumer Discretionary sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Energy, and Information Technology sectors. The S&P 500 Health Care Sector Index ended the day at 691.40, up 0.17%, with the index advancing 3.37% in the last one month. Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT) and Mallinckrodt PLC (NYSE: MNK). Free technical research on AVNR, ZTS, ACT and MNK can be downloaded upon signing up at:
Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...
New Employers Listed For Annual Life Science Hiring Event
PR Newswire - Mon Jun 02, 9:45AM CDT
HireLifeScience.com, the premier career networking website for the Life Science industries, will host its 5th annual career fair at The NJ Convention and Exposition Center at Raritan Center in Edison, NJ on September 30, 2014. The annual hiring event is being sponsored by Novo Nordisk. Additional event sponsors thus far include Covance and top generic drug company, Actavis, Inc. In addition to returning companies such as Johnson & Johnson, LifeCell and Cubist Pharmaceuticals there have been many companies added since April. Recent additions to the exhibitor list are Daiichi Sankyo, Musculoskeletal Transplant Foundation (MTF), DSM Nutritional Products, Acorda Therapeutics, GE Healthcare, Amneal Pharmaceuticals and Actavis, Inc. More companies will be added during the upcoming summer months creating the largest Life Science career fair for 2014 in the Tri-State area.
Enzo Biochem names James M O'Brien as senior VP of Finance
M2 - Mon Jun 02, 6:03AM CDT
Clinical laboratory company Enzo Biochem (NYSE:ENZ) revealed on Friday the election of James M O'Brien as senior vice president of its Finance, succeeding Andrew Crescenzo.
Actavis Announces Nuvigil® Patent Challenge Settlement
PR Newswire - Fri May 30, 3:05PM CDT
Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Cephalon, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Nuvigil® (armodafinil tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg). Nuvigil® is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy.
1 Big Pharma Stock in More Danger than Investors Realize
David Williamson, The Motley Fool - Motley Fool - Fri May 30, 1:05PM CDT
Eli Lilly (NYSE: LLY) just lost a patent fight for its lung cancer drug Alimta to generic drug maker Actavis (NYSE: ACT). This UK court decision would cut the blockbuster drug's patent short by 6 years to 2015, not only in the United Kingdom,...
Enzo Biochem Announces Appointment of James M. O'Brien as Senior VP, Finance
Business Wire - Fri May 30, 8:01AM CDT
Enzo Biochem, Inc. (NYSE:ENZ), a vertically integrated biosciences and clinical laboratory company, announced today the appointment of James M. O'Brien as Senior Vice President, Finance.
Many Weekly Review Stocks Still Nearing Buy Points
at Investor's Business Daily - Thu May 29, 5:50PM CDT
The market this week signaled a confirmed uptrend, which makes this a crucial time to find stocks to buy at proper buy points. Many leading stocks have already broken out past buy points. That's especially true in transportation, energy and food,...
Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.
Actavis Confirms Generic Onglyza® Patent Challenge
PR Newswire - Tue May 27, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza®, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Actavis Builds Base As Annual Earnings Keep Growing
at Investor's Business Daily - Fri May 23, 4:11PM CDT
It's been a busy year for Actavis (ACT) as it continues to grow through acquisitions. The former Watson Pharmaceuticals renamed itself Actavis after buying the latter drugmaker in 2012. In October it bought Irish pharmaceutical Warner Chilcott for...
Forest Laboratories, Inc. Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Thu May 22, 7:31AM CDT
Forest Laboratories, Inc. (NYSE: FRX) today announced that, subject to the close of the pending acquisition (the "Acquisition"
of Forest by Actavis plc (NYSE: ACT), Actavis is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations
PR Newswire - Thu May 22, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition"
of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. 
